![Kanya Rajangam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanya Rajangam
Plus aucun poste en cours
Fortune : 69 230 $ au 30/04/2026
Profil
Dr. Kanya Rajangam is a President & Chief Medical Officer at Senti Biosciences Holdings, Inc., a President, Chief Medical Officer, Head-R&D at Senti Biosciences, Inc. and an Independent Director at Turnstone Biologics, Inc. She is on the Board of Directors at Turnstone Biologics, Inc. Dr. Rajangam was previously employed as an Independent Director by Turnstone Biologics Corp., a Chief Medical Officer by Nkarta, Inc., a Chief Medical Officer & Senior Vice President by Atara Biotherapeutics, Inc., a Chief Medical Officer by Cleave Biosciences, Inc., an Executive Director by Nektar Therapeutics, a Senior Medical Director by Onyx Pharmaceuticals, Inc., and an Associate Medical Director by Exelixis, Inc. She received her doctorate degree from Northwestern University and a doctorate degree from St. John's Medical College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,16 % | 09/03/2026 | 74 843 ( 0,16 % ) | 69 230 $ | 30/04/2026 |
Postes actifs de Kanya Rajangam
| Sociétés | Poste | Début |
|---|---|---|
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Directeur/Membre du Conseil | 01/11/2011 |
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | President | 14/05/2024 |
Anciens postes connus de Kanya Rajangam
| Sociétés | Poste | Fin |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Directeur/Membre du Conseil | 11/08/2025 |
| NKARTA, INC. | Directeur Technique/Scientifique/R&D | 05/06/2022 |
| ATARA BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2018 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicine for oncology and neurodegeneration treatment | Directeur Technique/Scientifique/R&D | 01/07/2017 |
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | 01/05/2015 |
Formation de Kanya Rajangam
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which engages in developing innovative therapies that target the molecular mechanisms that cause cancer | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicine for oncology and neurodegeneration treatment | Health Technology |
St. John's Medical College
 St. John's Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Health Technology |
Nkarta, Inc.
 Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
Turnstone Biologics Corp.
 Turnstone Biologics Corp. BiotechnologyHealth Technology Develops and sells medicines to treat and cure solid tumors | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
